Systemic therapy of acne in conditions of war
Practical advice from an expert
The proposed article is an adaptation of a report announced on February 22, 2023 at the online conference Aesthetic Medicine: Time Challenges & Top Customer Requests organized by Estet Group. The full report can be viewed on the PRO Cosmetology TV channel.
Lyudmila Fedorych, MD, PhD, associate professor of dermatology and venereology at UMVA, top category dermatovenerologist (Ukraine)
With the beginning of the war, Ukrainians were forced to leave Ukraine and for some time remained without access to pharmacies and doctors. From February to May inclusive, we received numerous requests for acne treatment consultations. Among them were patients who took systemic isotretinoin (SI).
The SI molecule has been known on the global pharmaceutical market for over 40 years. SI was first synthesized in 1982, changing acne treatment standards and patients' lives forever. For the next 30 years, the search for a formula that would provide a powerful therapeutic effect with the lowest percentage of side effects continued.
Finally, in 2012, a form of SI with increased bioavailability was created. This opened a new stage in the effective treatment of patients with severe acne, who were given the opportunity to take the SI capsule independently of food, which greatly facilitated the calculation of the course dose and the overall management of acne for dermatologists. The FDA approved SI with extrabioavailability under the international name Isotretinoin Lidose in 2012.
Lidose® is a hard gelatin capsule filled with a liquid or semi-liquid lipid content. This technology makes it possible to use the capsule for the purpose of delivery: low dose substances; unstable substances sensitive to light, air or moisture; sparingly soluble (lipophilic) substances.
You can read the full article in Ukrainian